{"pmid":32386187,"title":"Antibody tests for COVID-19: drawing attention to the importance of analytical specificity.","text":["Antibody tests for COVID-19: drawing attention to the importance of analytical specificity.","Clin Chem Lab Med","Diamandis, Phedias","Prassas, Ioannis","Diamandis, Eleftherios P","32386187"],"journal":"Clin Chem Lab Med","authors":["Diamandis, Phedias","Prassas, Ioannis","Diamandis, Eleftherios P"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32386187","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1515/cclm-2020-0554","keywords":["covid-19","antibody","serological ab tests","widespread testing"],"topics":["Diagnosis"],"weight":1,"_version_":1666340102041763840,"score":9.490897,"similar":[{"pmid":32419875,"pmcid":"PMC7225716","title":"[Antibody tests for COVID-19: What the results tell us].","text":["[Antibody tests for COVID-19: What the results tell us].","Introduction: In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the detection of virus-specific antibodies (AB) will play an increasing role. The presence or absence of such antibodies can potentially lead to considerations regarding immunity and infection. Issue: How reliable are inferences from positive or negative test results regarding the actual presence of SARS-CoV-2 specific antibodies? Methods: Calculation of the probability that, depending on the pretest probability (prevalence of SARS-CoV-2 infection) and test properties, antibodies are present or absent in the case of positive or negative test results. Results: Sensitivity and specificity of different SARS-CoV-2 AB test systems vary between 53 % and 94 % and between 91 % and 99.5 %, respectively. When using a test with high test quality, the positive predictive value (PPV) is 42 % and 7 9%, respectively, with a pre-test probability of 1 % to 5 %, as can currently be assumed for the general population in Austria or Germany. For persons with an increased pre-test probability of 20 %, e. g. persons from high-risk professions, the PPW is 95 %, with a pre-test probability of 80 % the PPW is almost 100 %. The negative predictive value (NPV) is at least 99.7 % for persons with a low pre-test probability of up to 5 % and 79.1 % for persons with a pre-test probability of 80 %. When using test systems with lower sensitivity and specificity, the reliability of the results decreases considerably. The PPV is 5.9 % with a pre-test probability of 1 %. Conclusions: A sufficiently high sensitivity and specificity are prerequisites for the application of antibody test systems. Positive test results are often false if the pre-test probability is low. Depending on the assumed prevalence of a SARS-CoV-2 infection, there are substantial differences in the significance of a concrete test result for the respective affected persons.","Z Evid Fortbild Qual Gesundhwes","Horvath, Karl","Semlitsch, Thomas","Jeitler, Klaus","Krause, Robert","Siebenhofer, Andrea","32419875"],"abstract":["Introduction: In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the detection of virus-specific antibodies (AB) will play an increasing role. The presence or absence of such antibodies can potentially lead to considerations regarding immunity and infection. Issue: How reliable are inferences from positive or negative test results regarding the actual presence of SARS-CoV-2 specific antibodies? Methods: Calculation of the probability that, depending on the pretest probability (prevalence of SARS-CoV-2 infection) and test properties, antibodies are present or absent in the case of positive or negative test results. Results: Sensitivity and specificity of different SARS-CoV-2 AB test systems vary between 53 % and 94 % and between 91 % and 99.5 %, respectively. When using a test with high test quality, the positive predictive value (PPV) is 42 % and 7 9%, respectively, with a pre-test probability of 1 % to 5 %, as can currently be assumed for the general population in Austria or Germany. For persons with an increased pre-test probability of 20 %, e. g. persons from high-risk professions, the PPW is 95 %, with a pre-test probability of 80 % the PPW is almost 100 %. The negative predictive value (NPV) is at least 99.7 % for persons with a low pre-test probability of up to 5 % and 79.1 % for persons with a pre-test probability of 80 %. When using test systems with lower sensitivity and specificity, the reliability of the results decreases considerably. The PPV is 5.9 % with a pre-test probability of 1 %. Conclusions: A sufficiently high sensitivity and specificity are prerequisites for the application of antibody test systems. Positive test results are often false if the pre-test probability is low. Depending on the assumed prevalence of a SARS-CoV-2 infection, there are substantial differences in the significance of a concrete test result for the respective affected persons."],"journal":"Z Evid Fortbild Qual Gesundhwes","authors":["Horvath, Karl","Semlitsch, Thomas","Jeitler, Klaus","Krause, Robert","Siebenhofer, Andrea"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419875","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.zefq.2020.05.005","keywords":["antibody","negative predictive value","positive predictive value","pre-test probability","sars-cov-2"],"locations":["Austria","Germany"],"countries":["Austria","Germany"],"countries_codes":["AUT|Austria","DEU|Germany"],"topics":["Diagnosis"],"weight":1,"_version_":1667159284564099072,"score":67.09547},{"pmid":32389405,"title":"Understanding Antibody Testing for COVID-19.","text":["Understanding Antibody Testing for COVID-19.","The orthopedic community has seen the COVID-19 pandemic decimate elective surgical volumes in most geographies. Patients and essential workers, such as health care providers, remain rightfully concerned about how to appropriately begin to return to work and community activity in a safe and responsible manner. Many believe that testing for the presence of antibodies on a widespread scale could help drive evidence-based decision-making, both on an individual and societal scale. Much information, and an equal amount of misinformation, has been produced on antibody testing. Education about the role and science of such testing is critically important for programs to be effectively understood and managed.","J Arthroplasty","Jacofsky, David","Jacofsky, Emilia M","Jacofsky, Marc","32389405"],"abstract":["The orthopedic community has seen the COVID-19 pandemic decimate elective surgical volumes in most geographies. Patients and essential workers, such as health care providers, remain rightfully concerned about how to appropriately begin to return to work and community activity in a safe and responsible manner. Many believe that testing for the presence of antibodies on a widespread scale could help drive evidence-based decision-making, both on an individual and societal scale. Much information, and an equal amount of misinformation, has been produced on antibody testing. Education about the role and science of such testing is critically important for programs to be effectively understood and managed."],"journal":"J Arthroplasty","authors":["Jacofsky, David","Jacofsky, Emilia M","Jacofsky, Marc"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389405","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.arth.2020.04.055","keywords":["covid","covid-19","pcr","antibodies","antibody","coronavirus","screening","testing"],"topics":["Prevention"],"weight":1,"_version_":1666528580216029184,"score":58.401443},{"pmid":32358956,"pmcid":"PMC7197530","title":"Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.","text":["Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.","BACKGROUND: A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide. METHODS: We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen. RESULTS: 112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found. CONCLUSIONS: Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19.","J Infect Dis","Zhang, Guoxin","Nie, Shuke","Zhang, Zhaohui","Zhang, Zhentao","32358956"],"abstract":["BACKGROUND: A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide. METHODS: We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen. RESULTS: 112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found. CONCLUSIONS: Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19."],"journal":"J Infect Dis","authors":["Zhang, Guoxin","Nie, Shuke","Zhang, Zhaohui","Zhang, Zhentao"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358956","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/infdis/jiaa229","keywords":["covid-19","sars-cov-2","antibody","humoral immunity","serological test"],"locations":["fatigue","myalgia"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495305908224,"score":54.33942},{"pmid":32488946,"title":"No antibody response in acral cutaneous manifestations associated with COVID-19 ?","text":["No antibody response in acral cutaneous manifestations associated with COVID-19 ?","Skins symptoms during COVID-19 have been recently described but their relation to SARS-CoV-2 is unclear while results for real-time reverse transcriptase polymerase chain reaction (rRT-PCR) testing were variable. Recalcati et al. reported 14 cases of patients with skin symptoms consistent with previous described COVID-19 lesions but all the patients were tested negative. They asked for a serology to validate the hypothesis that these lesions are related to COVID-19.","J Eur Acad Dermatol Venereol","Mahieu, Rafael","Tillard, Lila","Le Guillou-Guillemette, Helene","Vinatier, Emeline","Jeannin, Pascale","Croue, Anne","Le Corre, Yannick","Vandamme, Yves-Marie","32488946"],"abstract":["Skins symptoms during COVID-19 have been recently described but their relation to SARS-CoV-2 is unclear while results for real-time reverse transcriptase polymerase chain reaction (rRT-PCR) testing were variable. Recalcati et al. reported 14 cases of patients with skin symptoms consistent with previous described COVID-19 lesions but all the patients were tested negative. They asked for a serology to validate the hypothesis that these lesions are related to COVID-19."],"journal":"J Eur Acad Dermatol Venereol","authors":["Mahieu, Rafael","Tillard, Lila","Le Guillou-Guillemette, Helene","Vinatier, Emeline","Jeannin, Pascale","Croue, Anne","Le Corre, Yannick","Vandamme, Yves-Marie"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32488946","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/jdv.16688","keywords":["antibody","covid-19","acral lesions","chilblain","cutaneous manifestations","perniosis"],"topics":["Diagnosis"],"weight":1,"_version_":1668892169258139648,"score":54.33942},{"pmid":32221519,"pmcid":"PMC7184337","title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.","text":["Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.","BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.","Clin Infect Dis","Zhao, Juanjuan","Yuan, Quan","Wang, Haiyan","Liu, Wei","Liao, Xuejiao","Su, Yingying","Wang, Xin","Yuan, Jing","Li, Tingdong","Li, Jinxiu","Qian, Shen","Hong, Congming","Wang, Fuxiang","Liu, Yingxia","Wang, Zhaoqin","He, Qing","Li, Zhiyong","He, Bin","Zhang, Tianying","Fu, Yang","Ge, Shengxiang","Liu, Lei","Zhang, Jun","Xia, Ningshao","Zhang, Zheng","32221519"],"abstract":["BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients."],"journal":"Clin Infect Dis","authors":["Zhao, Juanjuan","Yuan, Quan","Wang, Haiyan","Liu, Wei","Liao, Xuejiao","Su, Yingying","Wang, Xin","Yuan, Jing","Li, Tingdong","Li, Jinxiu","Qian, Shen","Hong, Congming","Wang, Fuxiang","Liu, Yingxia","Wang, Zhaoqin","He, Qing","Li, Zhiyong","He, Bin","Zhang, Tianying","Fu, Yang","Ge, Shengxiang","Liu, Lei","Zhang, Jun","Xia, Ningshao","Zhang, Zheng"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221519","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1093/cid/ciaa344","keywords":["covid-19","sars-cov-2","antibody"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1666138490458341376,"score":53.00643}]}